A C.D.C. panel discusses new rare clot cases in J. & J. shot recipients and how overall risk seems to be very low.
The U.S. government is likely to end the pause if the panel says the vaccine’s benefits outweigh the potential risk.
View original article
Contributor: Carl Zimmer and Emily Anthes
